

24 (New) The pharmaceutical composition of claim 23, wherein the disorder is selected from the group consisting of narcolepsy, attention deficit hyperactivity disorder, depression, Parkinson's disease, cognitive dysfunction, renal dysfunction, asthma, obesity, nicotine withdrawal, hypotension, apathy, pain and reduced energy associated with chemotherapy or radiation therapy.

REMARKS

The Examiner has rejected claims 1-8 under 35 USC 112, second paragraph, as indefinite because the language "an effective amount" used to describe the amount of (R,R'),(R,S')-amphetamine administered as in claim 1 does not designate the intended effect. Claims 2-8 depend on claim 1 and are rejected for the same reasoning.

The applicants herewith amend claim 1 so as to clarify that the applicants intend the pharmaceutical composition to be used for therapeutic purposes only by adding the word "therapeutically" before the language "effective amount". Once it is clear that the (R,R'),(R,S')-amphetamine is intended to be used therapeutically only, applicants believe that the specification provides sufficient guidance to the public as to what the metes and bounds of the invention are.

Furthermore, applicants have added new independent claim 23 and dependent claim 24 to further define the invention.

No new matter has been introduced by these amendments.

The applicants kindly request the present claims be allowed

Any questions about this response should be addressed to Karen Guerrero and the telephone number is 610-933-2490.

Sincerely,


Karen Guerrero

Registration No. 37,071